Preparation of virally inactivated intravenously injectable immune serum globulin
CA 2185859 C · Owner: Bayer Corporation · Inventors: Alonso, William R.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Method of reducing the anticomplement activity (ACA) resulting from viral inactivation treatment of a solution of antibodies the method comprising , contacting the solution with a trialkylphosphate, such as tri-n-butyl phosphate and a , detergent, such as , sodium cholate under conditions sufficient to reduce substantially the virus activity, and then , incubating the solution under controlled conditions of time pH, temperature, and ionic , strength such that the anticomplement activity is reduced to an acceptable level. In a preferred , embodiment, the ACA is reduced to less than 60 CH50 units/mL the incubation , is for at least , about ten days at a pH from 3.5 to 5.0 the temperature …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 18, 1996 and granted April 19, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 18, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 18, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.